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Can semiquantitative measurements of SUVmax and 
cut-off values differentiate colorectal malignant from 
benign lessions?
Abstract
Objectives: We investigated maximum standardized uptake value (SUVmax) and cut-oﬀ values for diﬀe-
rentiation of malignant and benign lesions in colorectal cancer (CC) as multiple studies have questioned 
their validity. We also investigated more extended indices using common semi-quanti cation analysis in 
incidental colorectal  ndings (ICF).  Subjects and Methods: Fluorine-18- uoro deoxy glucose positron 
emission tomography/computed tomography in 25 patients with a total of 30 focal ICF was retrospec-
tively analysed using dedicated software. Method variability was tested through application of three 
common threshold-based lesion delineation techniques as well as a partial-volume correction (PVC). Lesi-
on SUVmax, SUVmean, metabolically active volume (MAV) and mean total lesion glycolysis (TLG) were 
thereby extracted along with PVC corrected values (cSUVmean, cTLG) and SUVpeak. Results: In all lesions, 
SUVmax was >5 and SUVmean≥2.7. Malignant SUVmax values (mean±SD: 16.5±6.2) were overall 
signi cantly higher than benign levels (9.8±3.6). There was a substantial overlap with values in polyps/ 
adenomas (14.4±7.7). Both SUVpeak and SUVmean showed similar characteristics. Malignant MAV and 
TLG showed more distinct levels. Though diﬀerent segmentation methods introduced variations, largest 
in MAV (-58.6%-141.5%), and PVC generally increased measures signi cantly by a factor of 1.2-2.7, neither 
changed relative levels much. SUVmax values were inadequate for aetiological diﬀerentiation of ICF, 
which also precludes a clinically signi cant cut-oﬀ value. The same applies to SUVpeak and SUVmean 
while TLG measures may be more indicative. Conclusion: Semi-quantitative measurements of SUVmax 
and cut-oﬀ values proved inadequate for diﬀerentiating colorectal malignancies from benign  ndings. 
While integrated measures, e.g. cTLG, are potentially better indicators of disease severity and extent, more 
optimal segmentation and PVC methods are required.
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Introduction
Semi-quantitative measures for soft tissue mass classi cation have been explored in oncologic positron emission tomography (PET) studies using 2-deoxy-2-[ u-18orine-18- uoro-D-glucose ( F-FDG). Most prevalently, maximum standardized 
uptake value (SUVmax) is reported as the staple marker of lesion metabolic activity level. 
Cut-oﬀ values based on this to diﬀerentiate malignant from benign lesions are often 
relayed in the literature. For instance SUV≥2.5 is a widely adopted cut-oﬀ for malignancy 
[1, 2]. This remains common practice despite studies repeatedly questioning their gene-
ral validity [3, 4] as SUV reliability and comparability is in uenced by many factors [5]. 
Though SUVmax is simple to compute with high inter-observer reproducibility, it has 
shown to have a poorer inter-study repeatability than mean lesion uptake measures 
(SUVmean) [6-9]. As a single-voxel value, SUVmax is particularly susceptible to image 
noise and reconstruction parameters (e.g., smoothing, system response modelling, 
time-of- ight) with a shown noise level dependent bias [6, 10]. Variabilities in SUVmax of 
at least 10%-25% across diﬀerent centres are reportedly expectable [7, 11]. How well 
SUVmax and cut-oﬀ values indicate malignancy is therefore questionable.
Alternative measures have been suggested, but are still only sporadically investigated. 
This includes the more robust SUVpeak [5, 10] as well as SUVmean and total lesion glyco-
lysis (TLG) metrics that incorporate metabolic volume [12]. All depend on a region-of-in-
terest (ROI) de nition, which lacks standardized implementation, and are also more 
aﬀected by partial-volume eﬀect (PVE) [13]. Volumetric indices, nevertheless, oﬀer acco-
18unts of overall F-FDG uptake avidity and extent, which might provide better disease 
characterization if measured correctly. This, however, is yet to be established and would 
have high clinical value in improving diagnostics, prognostics, and treatment planning.
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Measures to better grade disease severity and extent is fur-
thermore especially desirable in response monitoring, whe-
re reliability of the standard single-voxel SUVmax can be 
compromised by its longitudinal instability. We therefore 
started systematic investigations of the utility of these semi-
quantitative metrics in such applications, addressing here 
 rst the prevalent employment for static disease indication. 
This assessment of semi-quantitative classi cation consi-
ders the proposed use in management of incidental colorec-
tal  ndings (ICF) as an exemplary high-impact clinical 
application. It is reported to occur in around 1%-4% of all pa-
18tients subject to F-FDG PET/CT [14-19] with a generally ac-
knowledged clinical signi cance of focal ICF, e.g., novel ma-
lignancies [19-24]. Current recommended invasive follow-
up assessment, such as colonoscopy [15, 25], could be avoi-
ded with PET lesion classi cation, which also entails the 
cross-study comparability challenges with scan variability 
typical of clinical settings. We evaluated such applied 
analysis using common methods available in commercial 
software. 
Subjects and Methods
Evaluation of quantitative assessment of soft tissue masses 
was conducted as a retrospective study on ICF in patients 
examined at our institution in 2011. Only those with 
colonoscopic results were included, which amounted to 25 
patients (13 female, 12 male, mean age±SD: 71±12yr.) with a 
total of 30 focal lesions (8 cancers, 13 polyps/adenomas, 9 
with only benign  ndings).
18F-FDG PET/CT imaging
The scan exams all employed the institutional standard pro-
tocol based on the guidelines of the European Association 
of Nuclear Medicine [26]. Patients were asked to fast for at 
least six hours prior to the exam and given oral water as a 
negative contrast agent. Positron emission tomography/ 
Computed tomography (PET/CT) was performed on four 
diﬀerent integrated scanners (GE Discovery STE, VCT, RX, 
and 690) and comprised: 1) Low-dose (<1mSv) CT scan (1-
13mAs, 120 or 140kV, 30-87mA, 10 or 40mm total collima-
tion width, pitch factor of 0.98-1.7, rotation time of 0.8s, ta-
ble speed of 21.9-68.8mm/s, table feed of 17.5-55mm/ rota-
tion, 50cm  eld-of-view) for attenuation correction in all 
patients. The CT image matrix was 512×512 with a voxel size 
3of 1.37×1.37×3.7mm . 2) Standard dose diagnostic CT scan 
(same scanner parameters as for CT scan 1) but with a pitch 
factor of 0.98-1.85) acquired dependent on indication with-
out or with intravenous contrast administration (Ultravist 
370mg/mL iodine concentration, dose range: 40-80mL). The 
CT image matrix was 512×512 with a voxel size of 
30.98×0.98×3.75mm . 3) Subsequent PET scan acquired on 
18average 73.8±14.3min after the injection of 4MBq/kg of F-
FDG (dose range: 198-402MBq). The scans covered the ver-
tex or base of the scull down to the mid-thigh, with 6-8 bed 
positions of 2-3.5min each (depending on patient body 
mass index) and acquired in three-dimensional (3D) mode.
Positron emission tomography image reconstructions 
were with the GE Advance scanner software (GE Healthcare, 
Waukesha, WI, USA), employing a standard 3D iterative or-
dered subset expectation maximization (OSEM) algorithm 
with all corrections (attenuation, randoms, deadtime, and 
normalization) incorporated within the iterative loop. A 
model-based scatter correction was also applied to data and 
reconstruction parameters were as detailed in Table 1.
Image analysis
To test ROI delineation variability and relate to literature 
reports, common approaches were applied with diﬀerent 
segmentation techniques as implemented in a commercial 
dedicated software tool (ROVER, ABX, Radeberg, Germany). 
Here PET image intensities were converted to SUV nor-
malized to body weight (BW) as the measure of distribution 
volume.  For each dataset a volume encompassing the le-
sion and at least 2-3 voxels away from the lesion boundaries 
was manually de ned. Subsequent analysis within this 
volume included automatic lesion detection with three seg-
mentation methods for lesion SUV extraction and a built-in 
partial-volume correction (PVC):
Table 1. Variations in PET reconstruction parameters used in exams on the GE Discovery (D) systems .
System GE D-STE GE D-VCT GE D-RX GE D-690
Matrix 6 9 9 1
3
Voxel size (mm ) 128×128 128×128 128×128 128×128
Algorithm 5.47×5.47×3.27 5.47×5.47×3.27 5.47×5.47×3.27 2.73×2.73×3.27
Iterations/subsets 3D OSEM 3D OSEM 3D OSEM 3D OSEM
Gaussian post-ﬁlter (mm FWHM) 2/28 2/28 2/21 3/18
Other PSF modelling PSF modelling PSF modelling PSF modelling+TOF
FWHM = full-width at half-maximum, PS = point spread function, TOF = time-of- ight
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1) Fixed 40% of SUVmax threshold (T40) based on 
guidelines [26] and reported use [16].
2) Adaptive background adjusted thresholds iteratively 
determined from an initial chosen isocontour at 40% of 
lesion SUVmax and calculated as [27]:
                                                                                                                         (1)
where SUVbg is the mean uptake in a 3D shell of sur-
rounding background with Eq. (1) evaluated globally for the 
entire lesion (LT method) or locally for each lesion relevant 
voxel (VT method).
3) Image-based PVC, where the lesion spill-out is estimated 
in a region, S, within a full-width at half-maximum (FWHM) 
distance from the estimated lesion (ROI) boundary. In this, 
the mean uptake, SUVspill, is found to yield the corrected 
lesion uptake as [28]:
                                                                                                             (2)
where A  is the measured activity and Abg the correspon-s
ding background level of voxel v in the spill-out region, VROI 
the ROI volume, D the decay corrected tracer dose (MBq) 
and BW the body weight (g).
No lower limit cut-oﬀ value was used in segmentations to 
avoid potential inclusion of background related voxels, 
which were instead removed manually when apparent on 
visual inspection. Within the resulting ROI delineations 
measures of SUVmax, SUVmean, metabolically active 
volume (MAV), mean TLG = SUVmean  MAV, and correspon-
ding PVE corrected cSUVmean and cTLG were obtained. 
Additionally, SUVpeak values were also recorded following 
guideline recommendations [26] as the mean SUV in a  xed 
1.2cm diameter spherical ROI centred at the voxel of 
SUVmax when such an area could be de ned within lesion 
delineations.
Statistical tests
Precursory comparisons between lesion groups (cancers, 
polyps/adenomas, benign  ndings) by Kruskal-Wallis test 
were performed and diﬀerences in derived semi-quantita-
tive lesion measures were evaluated for statistical signi -
cance by nonparametric two-sided Wilcoxon rank sum test. 
Changes with PVC and method variability were assessed by 
Wilcoxon signed-rank matched-pairs test. All statistical ana-
lyses were carried out using MATLAB 9.0 (Mathworks Inc.) 
and a statistical signi cance level of 5%.
Results 
Positron emission tomography/CT imaging presented a 
varied appearance of focal ICF with no visually conspicuous 
characteristics discerning one histological lesion type from 
the other. Overall 30% (9/30) of these showed irregular 
shape and/or clear heterogeneity of uptake, which especi-
ally caused various degrees of variation in ROI de nitions 
between segmentation methods as exempli ed in Figure 1.
Figure 1. Axial image example of focal ICF uptake (a) and corresponding lesion 
delineations employing a  xed 40% of SUVmax threshold (b), adaptive lesion- (c) 
and voxel-based thresholds (d). Variations are seen between the diﬀerent segmen-
ted ROI (overlaid in yellow-red colourmap).
Quantitative measures
Across all lesions, SUVmax was >5 and overlap in values was 
seen between histological groups (Figure 2a) with collec-
tively indistinct levels (P=0.2). Group results are given in Ta-
ble 2. Though SUVmax in malignancies compared to benign 
values on average were signi cantly higher (P=0.03) the le-
vels of polyps/adenomas were indistinguishable from both 
of these groups (P=0.38-0.49). Similarly, in all ROI deline-
ations, SUVmean  was ≥2.7 with no overall signi cant devi-
ations between lesion groups (P=0.12-0.21). With SUVmean 
on average higher in malignant than benign  ndings (P=0. 
01-0.04), the measures in polyps/adenomas again obscured 
any distinction (P=0.27-0.77) as is apparent in Figure 2b.
Figure 2. Semi-quantitative measures SUVmax (a), SUVmean (b), MAV (c), and 
TLG (d) extracted from lesion delineations using the VT segmentation method on 
each focal ICF in all three histological subgroups. Malignant and benign  ndings 
display overlap in SUV levels (a, b) and appear more distinct in volumetric me-
asures (c, d). Only lesion 7 in the polyps group was imaged with time-of- ight.
Volumetric measures, on the other hand, displayed some 
clearer separation of malignancies from polyps/adenomas 
and benign  ndings (Figure 2c-d). This was predominan-
tlydue to noticeable MAV peaks in cancers  well above the
Original Article
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measures of the other two lesion types, which had similar 
ranges. However,  uctuating MAV levels made the groups 
on the whole statistically indiscernible (P=0.06). While MAV 
varied with segmentation method (Table 2) the inter-group 
relations seen in Figure 2c were consistent across methods. 
Between groups, the larger malignant mean MAV were not 
signi cant compared to benign MAV (P=0.28-0.96). Polyp/ 
adenoma MAV, on the contrary, were generally smaller than 
both malignant (T40: P=0.06; LT, VT: P=0.03-0.05) and 
benign lesion MAVs (T40: P=0.05; LT, VT: P=0.09-0.20). Much 
of these volumetric relations carried over to TLG measures 
(Figure 2d, Table 2). Here, no signi cant relation was found in 
the average higher malignant values, above both benign 
(P=0.14-0.28) and polyp/adenoma TLG (P=0.06), which 
overall were lower than in benign  ndings (P=0.26-0.64).
An assessment of the combined relation between SUV 
and estimated lesion MAV (Figure 3) revealed no obvious 
correlation between lesion size and extracted measures of 
18F-FDG-uptake avidity. Although some lumping related to 
volumes of polyps/adenomas and benign  ndings appe-
ared in the low range, half of the malignant lesions were seen 
to fall within these levels. With the spread in SUV, no further 
characteristic clustering among lesion types was clearly ob-
served.
SUVpeak could not be de ned for  ve lesions, mainly 
when MAV <2.5mL. For values recorded, similar group level 
relations as seen for SUVmax in Figure 2a were found for 
SUVpeak (not shown). Average peak levels were in malig-
nant lesions 12.9±4.5 (n=7), polyps/adenomas 9.8±6.1 (n= 
10), and benign  ndings 7.5±3.1 (n=8). Further paralleling 
SUVmax were overall indistinguishable group ranges (P= 
0.12), where the distinction between malignant and benign 
 ndings (P=0.03) was obscured by the overlapping levels of 
polyps/adenomas (P=0.17-0.98).
Figure 3. SUVmax (a) and SUVmean (b) as a function of the estimated metabolic 
active volume (MAV) of each focal ICF in all three histological subgroups measured 
with the VT segmentation method.
Partial-volume correction
Application of the described PVC generally increased 
SUVmean and TLG measures signi cantly by a factor of 1.2-
2.7 (P<0.008). The corrections varied dependent on the seg-
mentation technique. However, within each method, cor-
rection of values in all lesions amounted to mere shifts as re-
lative group levels were largely preserved (Figure 4a-d). This 
remained the case when only correcting uptake measures in 
small lesions ≤2cm (Figure 4e-f ), where PVE typically is most 
pronounced. Hence no improvement in lesion type separa-
bility for SUVmean was achieved with the employed PVC, 
which also left the distinctions in TLG unchanged.
Method variability
A 10%-70% of the threshold-based segmentations (T40: 
3/30, LT: 8/30, VT: 21/30) gave improper lesion delineations
Table 2. Results obtained with the three segmentation methods for all histological lesion groups.
Measure Method
Cancers
(mean±SD)
Polyps/Adenomas
(mean±SD)
Benign ﬁndings
(mean±SD)
SUVmax T40, LT, VT 16.5±6.2 14.4±7.7 9.8±3.6
SUVmean
T40 9.73±3.34 9.08±5.19 5.83±2.37
LT 10.21±3.45 9.47±5.23 6.36±2.24
VT 8.81±2.83 8.98±5.08 5.94±2.17
MAV  (mL)
T40 14.74±14.82 3.98±3.92 10.27±12.31
LT 12.76±13.26 3.41±3.68 6.36±6.03
VT 20.86±22.18 4.12±4.84 10.11±13.22
TLG
T40 162.95±189.00 35.18±42.35 60.42±69.31
LT 147.63±175.01 32.53±41.05 46.00±58.27
VT 203.61±241.18 36.55±47.58 59.87±73.36
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that included irrelevant voxels, which had to be manually 
excluded. Across all these segmentations, SUVmax was 
reproducible (Figure 5a). On the other hand, MAV measu-
rement varied the most (Figure 5b) between -58.6%-141.5% 
among delineation techniques. This translated into inter-
method variations of -20.2%-25.2% in SUVmean and -48.7% 
-94.9% in TLG (Figure 5c-d). Irrespective of these diﬀerences 
in measured values the lesion group level relations shown in 
Figure 2 were overall consistently found across methods. 
The further impact of PVC for each segmentation did not 
yield a larger between-method agreement in measure-
ments. In fact, increased spread in method diﬀerences of -
38.9%-63.6% in cSUVmean was recorded (Figure 5e), albeit 
with collectively decreased variations of -38.2%-61.8% in 
cTLG (Figure 5f ). In none of the ROI delineation approaches 
did these corrected uptake estimates overall alter the 
corresponding uncorrected relations seen in Figure 2. On 
the whole, LT method measures, without and with PVC, de-
viated signi cantly (P<0.02) from the more concordant re-
sults of the T40 and VT methods.
Discussion
Within common clinical settings and procedures, analysis of 
PET scans of ICF clearly showed SUVmax to be an insuf-
 cient marker of aetiology (i.e., malignant, polyp/adenoma, 
or benign). The displayed overlap between lesion types ec-
hoes multiple reports in the literature [16, 21, 23, 29-32], 
where uptake levels were also noted to be inconsistent bet-
ween studies (Figure 6). Although some report positive 
discriminatory qualities [19, 32-34], a seemingly larger 
number writes oﬀ SUVmax as a stand-alone tool for diﬀeren-
tiating histology [14, 17, 18, 25, 29]. The further collective 
lack of proven reproducibility of favourable  ndings and 
high inter-study variability seen in the literature speaks to an 
absence of general validity. Given the broad test-retest vul-
nerability seen in SUVmax even with harmonized proce-
dures [9], this altogether substantiates that SUVmax cannot 
casually be relied on for accurate indication of malignancy.
Reported reference values are then also more likely study-
dependent, particularly cut-oﬀ suggested to signify malig-
nancy. As is apparent from the present study, any SUVmax 
cut-oﬀ de ned will not be clinically signi cant. The widely 
reported overlap in uptake levels veri ed here would ine-
vitably entail mislabelling with cut-oﬀs based on SUVmax 
alone. Such inapplicability and the discordant reports are 
seen among studies of both small (<50) [19, 23, 25, 29] and 
larger sample sizes (>100) [14, 18, 34]. It is therefore in all 
probability measurement variability rather than histopatho-
logical signi cance that marks SUVmax cut-oﬀ de nitions as 
also evident from inconsistent values between 2.5-11.4 
proposed in the literature [14, 16, 18, 31-33]. In fact, this ap-
Original Article
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Figure 4. SUVmax (a) and SUVmean (b) as a function of the estimated metabolic active volume (MAV) of each focal ICF in all three histological subgroups measured with 
the VT segmentation method.
pears to apply generally to reports of such cut-oﬀ for malig-
nancy with a divergence in values within and across soft tis-
sue pathologies (Table 3). Certainly, the notion of a uni-
versally signi cant cut-oﬀ, such as 2.5, is arbitrary and must 
be dismissed. Diversities in technical aspects, procedures 
and methodology typical of clinical settings among facilities 
imply that suggested cut-oﬀ values prevalently are at best 
centre-dependent. Results on ICF in this study and others 
represent well the practice and outcome variability one mig-
ht expect in these scenarios, showing limitations to the use 
of SUVmax and derived cut-oﬀ values. Such applications 
may improve with method standardisations as broadly cal-
led for. However, the degree of test-retest repeatability re-
mains an issue that must be accounted for in clinical trials.
SUVpeak suggested for increased inter-study robustness 
was no more discriminatory than SUVmax in this study. Its 
application furthermore was limited by and would depend 
on the ROI de nition, which can vary in implementation. 
Hence SUVpeak will not be more reliable for aetiological 
diﬀerentiation than SUVmax or SUVmean as it ranges some-
where between the two. In small lesions, SUVpeak tends 
towards being a ROI-speci c SUVmean measure, which 
across delineation methods did not provide adequate dis-
tinctions either in this study. Relative SUVmean levels be-
tween lesion groups actually resembled those seen in 
SUVmax. Such could allude to a correspondence between 
the two as has also been found previously [32], perhaps me-
rely re ecting the general grade of SUV measurements and 
predominant levels in ICF uptake distributions.
Figure 6. Literature reports on mean SUVmax and standard deviations (bars) or 
18ranges (dashed lines) for diﬀerent categories of focal ICFs in F-FDG PET/CT.
Evaluation of alternative volumetric measures, MAV and 
TLG, showed somewhat clearer separation of malignant and 
non-malignant lesions. This is contrary to another study 
reporting less discriminatory eﬃcacy of MAV than SUVmax 
[32], which may be due to study dissimilarities. That MAV in 
this study nonetheless yielded better distinction of 
particularly polyps/adenomas whereas SUVs overall were 
only distinct between malignant and benign  ndings 
resembles that reported by Oh et al. (2012) [16]. Such would 
Figure 5. Bland-Altman plots of relative diﬀerences in measured SUVmax (a), MAV (b), SUVmean (c), TLG (d), and PVE corrected cSUVmean (e) and cTLG (f) between the 
three segmentation methods (T40, LT, VT), respectively. Solid and dashed lines indicate mean±2SD.
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indicate a better diﬀerentiation based on combined measu-
res rather than on any single index. Although their proposed 
compounded two-fold cut-oﬀ approach seems promising 
some misclassi cation occurred. Our study found no ob-
vious correlation between MAV and SUV. Instead, the over-
laps between subgroups found here (Figure 3) would imply 
a risk of false labelling for any de ned set of cut-oﬀ. It is still 
further clear that such combined cut-oﬀs will be just as 
study-dependent as a unilateral cut-oﬀ might be given the 
variation in measurements observed. Even so, integrating 
both activity extent and level appears to oﬀer greater chara-
cteristics since the blended TLG measure alone showed 
better distinction of malignancy than either SUV or MAV in 
our study. TLG in this context has apparently been little 
investigated to date as we found only one recent study re-
porting on TLG for ICF classi cation [35]. A favourable ap-
plication of MAV and TLG was recounted there too.
Irrespective of the applied semi-quantitative index none 
of the ICF studies in the literature we reviewed dealt expli-
citly with the potential biases induced by PVE. Considering 
the range of reported ICF sizes many cases would expec-
tedly be aﬀected. As PVE is study and anatomy dependent 
such unaccounted errors stand for additional variability par-
ticularly in SUVmean and TLG estimates. This can explain 
some  uctuations in these measures for lesion subgroups. 
Possible corrections with an image-based technique yiel-
ded shifted levels but overall unaltered relations. A con r-
mation of observed relative levels was, however, not neces-
sarily obtained by that. It perhaps more likely re ects that 
the image-based PVC method employed is too simple and 
inadequate as corrections were also shown to be segmen-
tation-dependent. As PVE is the same in any given lesion, its 
correct estimation and correction should be invariable with 
the applied methods. Nonetheless, the signi cant correc-
tion factors of 1.2-2.7 computed in this study can indicate 
that PVE in lesions like these is non-negligible as expected. 
Hence results in this regard remain inconclusive. More pro-
per PVC techniques are called for to reliably assess the utility 
of the aﬀected SUV-based measures. PVE must not at any 
rate be left out of the equation, as has been the case so far.
The threshold-based segmentation methods proved 
insuﬃcient with variable results, here often requiring manu-
al processing that increase variability. It can further be infer-
red from Figure 5 that diﬀerent ROI de nitions also has a di-
rect impact on absolute quantitative results. Therefore, any
Original Article
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Table 3. Reported SUVmax cut-off values for malignancy in 
various soft tissue masses
Type First author 
(year)
Threshold 
deﬁnition
Threshold
(s)
Colo-
rectal 
ﬁndings
Weston 
(2010) [31]
True possitive 
cut-off
3.5
Luboldt 
(2010) [32]
Best  cut-off 5.0
Peng (2011) 
[14]
Uptake-
positive cut-
off
2.5
Oh (2012) 
[16]
Best cut-off 9.1
Cho (2013) 
[33]
Best cut-off 5.05
van Hoeij 
(2015) [18]
Best cut-off 11.4
Non-
small 
cell lung 
cancer
Jeong 
(2002) [36]
Best cut-off 7.0
Sasaki 
(2003) [37]
Best cut-off 5.0
Van 
Baardwijk 
(2007) [38]
Best cut-off 8.0/11.0
Al-Sarraf 
(2008) [39]
Best cut-off 15.0
Thoracic 
lymph 
node 
metastas
es
Bryant 
(2006) [40]
Best cut-off 5.3
Tournoy 
(2007) [41]
Best cut-off 2.9
Bella (2014) 
[42]
Best cut-off 4.1
Bryant 
(2006) [40]
Diagnostic 
criteria
2.5
Tasci (2010) 
[43]
Diagnostic 
criteria
5.2
Pulmo-
nary 
nodes
Degirmenci 
(2008) [44]
Best cut-off 2.4
Grgic (2010) 
[45]
Best cut-off 4.0
Huang 
(2012) [46]
Best cut-off 5.05
Lopez 
(2015) [47]
Best cut-off 1.95
Adrenal 
lesions
Okada (2009) 
[2]
Best cut-off 2.5
Ozcan (2011) 
[48]
Best cut-off 4.2
Kunikowska 
(2014) [49]
Best cut-off 5.2
Launay 
(2015) [50]
Best cut-off 3.7
cut-oﬀ value based on ROI-dependent measures will clearly 
not have general validity if diﬀerent segmentation appro-
aches are employed. The variability is clearly seen in the hig-
hly method-dependent volume estimates with the largest 
variation among all measures of up to 141.5%. However, the 
fact that the corresponding SUVmean and TLG measures 
diﬀer less among methods signi es the inherent robustness 
in applying region averaging. Such would also underlie 
reported higher inter-study reproducibility compared to 
SUVmax. Of course SUVmean variability would increase 
with the degree of heterogeneity, where alternatively 
SUVmax is rendered even more unlikely to re ect overall 
metabolism well. In this study, diﬀerent segmentations yiel-
ded diﬀerent biases in absolute measurements, but similar 
relative levels between lesion subgroups were found irres-
pective of method. This might just re ect that the within-
method bias is the same and inhomogeneity was only to 
such a degree that diﬀerences in biases between methods 
then amount to relative value shifts. More accurate PVC 
would expectedly increase the consistency in TLG and 
SUVmean measurements across delineation methods.
Inter-study standardization will heighten comparability of 
uptake measures, but is limited still by practical variability 
and the degree of repeatability. In this study, the inter-met-
hod shifts in scale with overall consistent lesion uptake re-
lations further imply that relative rather than absolute scale-
dependent comparisons should be preferred. In any res-
pect, proper ROI de nition matters, especially with highly 
inhomogeneous uptake. Thus, improved analyses with mo-
re robust and reliable segmentations and PVC need to be 
developed to accurately assess the utility of extended ROI 
measures for better disease characterization.
In conclusion, this study of ICF demonstrated that the 
prevalently used SUVmax measure is insuﬃcient for 
aetiological diﬀerentiation of lesions. No useful concom-
itant cut-oﬀ value for malignancy could be de ned as such 
often reported values also will be highly study-dependent. 
Semi-quantitative analysis with common methods showed 
that alternative measures such as SUVpeak and SUVmean 
are no better as single markers. A combination of measures 
rather than any particular index might provide better 
classi cation as the compounded TLG alone indicated larger 
histological distinctions by integrating metabolic volume 
and activity level. The variability of absolute uptake est-
imates and consistent relative levels seen with diﬀerent seg-
mentations and PVC depend on the accuracy of both met-
hods. As the common threshold-based segmentation and 
simple PVC methods employed in this study proved sub-
optimal it remains to be assessed whether improved met-
hods can provide measures, e.g., cTLG, that better re ect the 
disease severity and extent than SUVmax values.
The authors of this study declare no con ict of interest
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